Compare VABK & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | ACRS |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.8M | 230.8M |
| IPO Year | N/A | 2015 |
| Metric | VABK | ACRS |
|---|---|---|
| Price | $40.47 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 9.1K | ★ 1.4M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 14.22 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $56,512,000.00 | $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.28 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $33.66 | $1.05 |
| 52 Week High | $44.57 | $4.24 |
| Indicator | VABK | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 64.58 |
| Support Level | $38.11 | $2.34 |
| Resistance Level | $39.38 | $2.57 |
| Average True Range (ATR) | 0.90 | 0.21 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 100.00 | 87.31 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.